查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880418

藥物定序市場預測至2032年：按治療領域、藥物類型、應用、最終用戶和地區分類的全球分析

Drug Repurposing Market Forecasts to 2032 - Global Analysis By Therapeutic Area, Drug Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，全球藥物定序市場預計到 2025 年價值 4.6 億美元，預計到 2032 年將達到 14 億美元，在預測期內以 17.0% 的複合年成長率成長。

藥物定序是指發掘已獲已通過核准或正在研發的藥物的其他醫療用途。透過利用現有藥物的安全性和作用機制知識來識別新的疾病標靶，可以降低研發成本、縮短開發週期並最大限度地減少安全性方面的不確定性。因此，藥物重定位在快速提供有效治療方面發揮重要作用，尤其是在癌症、神經系統疾病和感染疾病等治療難度較高的領域。

慢性病負擔日益加重

藥物定序因其比傳統藥物發現和開發速度更快、成本更低而備受關注。隨著人口老化和診斷技術的進步，已開發國家和新興國家對新治療途徑的需求日益成長。再利用藥物正擴大被納入個人化醫療策略，有助於改善患者預後並縮短治療週期。計算生物學和人工智慧驅動的篩檢的進步正在加速現有化合物新用途的發現。慢性疾病負擔的日益惡化是推動藥物定序市場擴張的主要因素。

經濟獎勵有限

仿單標示外用藥的專利保護通常較弱，降低了長期盈利潛力。法規結構複雜，新適應症的藥物核准路徑也可能不明朗。缺乏強而有力的報銷和獎勵機制，小規模公司難以將資源投入仿單標示外計劃。缺乏強力的資金支持會減緩創新，並抑制對細分治療領域的投資。因此，有限的經濟獎勵仍是阻礙因素市場成長的主要因素。

罕見疾病治療

藥物定序為治療罕見疾病和難治性疾病提供了獨特的機會。由於傳統藥物研發的商業性吸引力較低，這些疾病往往缺乏有效的治療方法。再利用的藥物可以繞過漫長的藥物研發階段，使服務不足的患者群體能夠更快地獲得治療。監管機構也日益支持藥物再利用，提供孤兒藥認定和加速核准等獎勵。基因組學和生物標記識別技術的進步，使得針對更罕見疾病的標靶藥物再利用策略成為可能。對罕見疾病的日益關注，正在為市場拓展開闢新的途徑。

新環境下的安全性和有效性問題

臨床療效會因患者人口統計學特徵、劑量和疾病生物學特性而顯著不同。監管機構要求進行廣泛的測試，以確保藥物再利用符合嚴格的安全標準。意外的副作用或療效降低可能會削弱人們對再利用療法的信心。這些風險可能導致商業化進程延遲，並增加製藥公司的研發成本。因此，對安全性和有效性的擔憂對藥物定序市場構成持續的威脅。

新冠疫情的影響：

新冠疫情加速了人們對藥物定序的興趣，研究人員急需尋找即時的治療方案。多種現有藥物的抗病毒特性得到了評估，凸顯了它們在緊急情況下重新利用的潛力。各國政府、學術界和產業界之間的全球合作得到加強，促成了快速的臨床試驗和緊急使用授權。然而，供應鏈中斷和試驗結果的不一致給藥物的持續應用帶來了挑戰。疫情也凸顯了建構具有韌性的法規結構和製定適應性強的研發策略的重要性。

預計在預測期內，腫瘤治療領域將佔據最大的市場佔有率。

預計在預測期內，腫瘤領域將佔據最大的市場佔有率。癌症複雜的生物學特性和巨大的未滿足治療方法需求使其成為藥物再利用的關鍵領域。現有藥物正被評估用於新的腫瘤適應症，從而縮短研發時間和降低成本。醫院和研究機構擴大採用再利用的腫瘤藥物來拓展治療選擇。精準醫療和生物標記主導療法的進步進一步推動了這一趨勢。隨著全球癌症發生率的持續上升，腫瘤領域仍然是藥物定序的最大領域。

預計在預測期內，學術和研究機構板塊的複合年成長率將最高。

預計在預測期內，學術和研究機構板塊將實現最高成長率，因為這些機構在藥物再利用的早期發現和檢驗中發揮關鍵作用。與製藥公司和政府機構的合作計劃正在拓展其研究能力。大學正利用運算建模和人工智慧的進步來加速藥物再利用的研發進程。轉化研究經費的不斷成長也進一步推動了該板塊的成長。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度和日本等國正大力投資醫療基礎設施和藥物研發。政府主導的措施正在推動本地藥物開發和再利用策略，旨在降低成本。慢性病盛行率的上升和大規模的患者群體正在推動對價格合理的治療方法的需求。學術合作和臨床試驗網路正在全部區域擴展，從而促進了藥物的快速應用。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率。強勁的研發投入和先進的醫療基礎設施為創新提供了沃土。美國和加拿大在人工智慧藥物研發和精準醫療應用方面處於主導地位。 FDA等監管機構正在簡化老藥新核准流程，加速藥物商業化進程。完善的健保體系和新治療方法的高普及率進一步推動了市場成長。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球藥物定序市場（依治療領域分類）

  • 介紹
  • 腫瘤學
  • 神經病學
  • 感染疾病
  • 心血管疾病
  • 自體免疫疾病與發炎性疾病
  • 罕見疾病
  • 代謝紊亂
  • 其他治療領域

6. 全球藥物定序市場（依藥物類型分類）

  • 介紹
  • 小分子
  • 生物製藥

7. 全球藥物定序市場（依應用領域分類）

  • 介紹
  • 發現新的適應症
  • 線路延長
  • 處方變更和聯合治療
  • 其他用途

8. 全球藥物定序市場（依最終用戶分類）

  • 介紹
  • 製藥和生物技術公司
  • 學術研究機構
  • 合約研究組織（CRO）
  • 醫療保健提供者
  • 其他最終用戶

9. 全球藥物定序市場（依地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第11章 企業概況

  • Recursion Pharmaceuticals
  • Pfizer
  • Healx
  • NuMedii
  • BenevolentAI
  • BioXcel Therapeutics
  • Evotec SE
  • Rejuvenate Biomed
  • Exscientia
  • Melior Discovery
  • Insilico Medicine
  • Pharnext
  • Lantern Pharma
  • Standigm
  • Biovista
Product Code: SMRC32560

According to Stratistics MRC, the Global Drug Repurposing Market is accounted for $0.46 billion in 2025 and is expected to reach $1.40 billion by 2032 growing at a CAGR of 17.0% during the forecast period. Drug repurposing involves discovering additional medical applications for drugs that are already approved or under development. It leverages existing knowledge about a drug's safety and mechanism of action to find new disease targets. This strategy lowers research costs, shortens development timelines, and minimizes safety uncertainties. As a result, repurposing plays a crucial role in quickly delivering effective treatments, especially in challenging therapeutic fields such as cancer, neurological disorders, and infectious diseases.

Market Dynamics:

Driver:

Rising chronic disease burden

Drug repurposing is gaining traction as it offers faster and more cost-effective solutions compared to traditional drug development. With aging populations and improved diagnostic capabilities, the demand for novel treatment pathways is expanding across both developed and emerging economies. Repurposed drugs are increasingly being integrated into personalized medicine strategies, enhancing patient outcomes and reducing treatment timelines. Advances in computational biology and AI-driven screening are accelerating the identification of new uses for existing compounds. This rising chronic disease burden is therefore a major catalyst for the expansion of the drug repurposing market.

Restraint:

Limited financial incentives

Patent protection is often weaker for repurposed drugs, reducing the potential for long-term profitability. Regulatory frameworks can be complex, with unclear pathways for approval of drugs in new indications. Smaller firms struggle to allocate resources toward repurposing projects without strong reimbursement or incentive structures. The lack of robust financial backing slows innovation and discourages investment in niche therapeutic areas. Consequently, limited financial incentives remain a significant restraint on market growth.

Opportunity:

Orphan and rare disease treatment

Drug repurposing presents a unique opportunity in the treatment of orphan and rare diseases. These conditions often lack effective therapies due to limited commercial appeal for traditional drug development. Repurposed drugs can bypass lengthy discovery phases, offering faster access to treatments for underserved patient populations. Regulatory agencies are increasingly supportive, providing incentives such as orphan drug designations and expedited approval pathways. Advances in genomics and biomarker identification are further enabling targeted repurposing strategies for rare conditions. This growing focus on orphan and rare diseases is opening new avenues for market expansion.

Threat:

Safety and efficacy concerns in a new context

Clinical outcomes may vary significantly depending on patient demographics, dosage, and disease biology. Regulatory authorities demand extensive testing to ensure that repurposed drugs meet rigorous safety standards. Unexpected side effects or reduced effectiveness can undermine confidence in repurposed therapies. These risks can delay commercialization and increase development costs for pharmaceutical firms. As a result, safety and efficacy concerns represent a persistent threat to the drug repurposing market.

Covid-19 Impact:

The Covid-19 pandemic accelerated interest in drug repurposing as researchers sought immediate solutions for treatment. Several existing drugs were evaluated for antiviral properties, highlighting the potential of repurposing in emergency contexts. Global collaboration between governments, academia, and industry intensified, leading to rapid clinical trials and emergency authorizations. However, supply chain disruptions and inconsistent trial results created challenges for sustained adoption. The pandemic also emphasized the importance of resilient regulatory frameworks and adaptive R&D strategies.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to account for the largest market share during the forecast period. Cancer's complex biology and high unmet medical need make it a prime area for repurposed therapies. Existing drugs are being evaluated for new oncological applications, reducing development timelines and costs. Hospitals and research institutes are increasingly adopting repurposed oncology drugs to expand treatment options. Advances in precision medicine and biomarker-driven approaches are further supporting this trend. As cancer incidence continues to rise globally, oncology remains the largest segment in drug repurposing.

The academic & research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the academic & research institutes segment is predicted to witness the highest growth rate, due to these institutions play a critical role in early-stage discovery and validation of repurposed drugs. Collaborative projects with pharmaceutical companies and government agencies are expanding research capacity. Advances in computational modeling and AI are being leveraged by universities to accelerate repurposing pipelines. Increased funding for translational research is further boosting growth in this segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share. Countries such as China, India, and Japan are investing heavily in healthcare infrastructure and pharmaceutical R&D. Government initiatives are promoting local drug development and encouraging repurposing strategies to reduce costs. Rising chronic disease prevalence and large patient populations are driving demand for affordable therapies. Academic collaborations and clinical trial networks are expanding across the region, supporting rapid adoption.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Strong R&D investments and advanced healthcare infrastructure provide a fertile environment for innovation. The U.S. and Canada are leading in AI-driven drug discovery and precision medicine applications. Regulatory agencies such as the FDA are streamlining pathways for repurposed drugs, encouraging faster commercialization. Robust reimbursement systems and high adoption of novel therapies further support market growth.

Key players in the market

Some of the key players in Drug Repurposing Market include Recursion, Pfizer, Healx, NuMedii, Benevolent, BioXcel Th, Evotec SE, Rejuvenate, Exscientia, Melior Dis, Insilico Me, Pharnext, Lantern Ph, Standigm, and Biovista.

Key Developments:

In November 2025, Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transaction it's a deliberate investment in the future of medicine.

In October 2024, Recursion and Google Cloud announced an expanded collaboration leveraging Google Cloud's technologies to support Recursion's drug discovery platform. This strategic partnership includes exploring generative AI capabilities, including Gemini models, to support the RecursionOS, drive improved search and access with BigQuery, and help scale compute resources.

Therapeutic Areas Covered:

  • Oncology
  • Neurology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Autoimmune & Inflammatory Diseases
  • Rare Diseases
  • Metabolic Disorders
  • Other Therapeutic Areas

Drug Types Covered:

  • Small Molecules
  • Biologics

Applications Covered:

  • New Indications Discovery
  • Line Extension
  • Reformulation & Combination Therapy
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Healthcare Providers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Repurposing Market, By Therapeutic Area

  • 5.1 Introduction
  • 5.2 Oncology
  • 5.3 Neurology
  • 5.4 Infectious Diseases
  • 5.5 Cardiovascular Diseases
  • 5.6 Autoimmune & Inflammatory Diseases
  • 5.7 Rare Diseases
  • 5.8 Metabolic Disorders
  • 5.9 Other Therapeutic Areas

6 Global Drug Repurposing Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Small Molecules
  • 6.3 Biologics

7 Global Drug Repurposing Market, By Application

  • 7.1 Introduction
  • 7.2 New Indications Discovery
  • 7.3 Line Extension
  • 7.4 Reformulation & Combination Therapy
  • 7.5 Other Applications

8 Global Drug Repurposing Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biotechnology Companies
  • 8.3 Academic & Research Institutes
  • 8.4 Contract Research Organizations (CROs)
  • 8.5 Healthcare Providers
  • 8.6 Other End Users

9 Global Drug Repurposing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Recursion Pharmaceuticals
  • 11.2 Pfizer
  • 11.3 Healx
  • 11.4 NuMedii
  • 11.5 BenevolentAI
  • 11.6 BioXcel Therapeutics
  • 11.7 Evotec SE
  • 11.8 Rejuvenate Biomed
  • 11.9 Exscientia
  • 11.10 Melior Discovery
  • 11.11 Insilico Medicine
  • 11.12 Pharnext
  • 11.13 Lantern Pharma
  • 11.14 Standigm
  • 11.15 Biovista

List of Tables

  • Table 1 Global Drug Repurposing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Drug Repurposing Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 3 Global Drug Repurposing Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 4 Global Drug Repurposing Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 5 Global Drug Repurposing Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 6 Global Drug Repurposing Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 7 Global Drug Repurposing Market Outlook, By Autoimmune & Inflammatory Diseases (2024-2032) ($MN)
  • Table 8 Global Drug Repurposing Market Outlook, By Rare Diseases (2024-2032) ($MN)
  • Table 9 Global Drug Repurposing Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
  • Table 10 Global Drug Repurposing Market Outlook, By Other Therapeutic Areas (2024-2032) ($MN)
  • Table 11 Global Drug Repurposing Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 12 Global Drug Repurposing Market Outlook, By Small Molecules (2024-2032) ($MN)
  • Table 13 Global Drug Repurposing Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 14 Global Drug Repurposing Market Outlook, By Application (2024-2032) ($MN)
  • Table 15 Global Drug Repurposing Market Outlook, By New Indications Discovery (2024-2032) ($MN)
  • Table 16 Global Drug Repurposing Market Outlook, By Line Extension (2024-2032) ($MN)
  • Table 17 Global Drug Repurposing Market Outlook, By Reformulation & Combination Therapy (2024-2032) ($MN)
  • Table 18 Global Drug Repurposing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 19 Global Drug Repurposing Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Drug Repurposing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 21 Global Drug Repurposing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 22 Global Drug Repurposing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 23 Global Drug Repurposing Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 24 Global Drug Repurposing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.